Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002974 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis
A Phase 2 study, sponsored by Swedish Orphan Biovitrum.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT03002974 is a Phase 2 study that has completed, run by Swedish Orphan Biovitrum. The registered enrollment target is 165 participants.
The verdict
NCT03002974, a Phase 2 study, has completed, sponsored by Swedish Orphan Biovitrum.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how anakinra relieves pain for patients with acute gout that cannot take non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine. The patients will be divided in different treatment groups to compare anakinra to the available drug triamcinolone.
Interventions
- DRUG Anakinra 100 mg
- DRUG Triamcinolone Acetonide 40 mg
- DRUG Placebo to Anakinra 100 mg
- DRUG Placebo to Triamcinolone Acetonide 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03002974
The ClinicalTrials.gov registry entry for NCT03002974 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swedish Orphan Biovitrum, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Anakinra 100 mg is the first listed.
NCT03002974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03002974 about?
NCT03002974 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis". The purpose of this study is to evaluate how anakinra relieves pain for patients with acute gout that cannot take non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine. The patients will be divided in different treatment groups to compare anakinra to the available drug triamcinolone.
What is the current status of trial NCT03002974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2016-12. Estimated completion is 2019-08.
What interventions are being tested in trial NCT03002974?
The interventions under investigation include: Anakinra 100 mg (DRUG), Triamcinolone Acetonide 40 mg (DRUG), Placebo to Anakinra 100 mg (DRUG), Placebo to Triamcinolone Acetonide 40 mg (DRUG).
Who is sponsoring clinical trial NCT03002974?
This trial is sponsored by Swedish Orphan Biovitrum, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.